World

~

An Oxford vaccination trial – testing the effectiveness of the ChAdOx1 nCoV-19 vaccine – has moved to South Africa, Brazil, and the United States after seeing success in the United Kingdom 

PHOTO CREDITS: CLAUDIO FURLAN/AP

According to CBS News, an Oxford vaccination trial – testing the effectiveness of the ChAdOx1 nCoV-19 vaccine – has shifted from the United Kingdom to South Africa, Brazil, and the United States. The original trial, involving ten thousand participants from the United Kingdom, is now thought to may not have results that are conclusive enough to prove the vaccine works. This is due to the plummeting amount of active COVID-19 cases in the United Kingdom. The trial needed to be tested in an area with more cases to ensure that it can prove if the vaccine works or not, hence the move by researchers to shift the trial to South Africa, Brazil, and the United States. ~

South Africa and Brazil are both fighting some of the most dangerous COVID-19 epidemics in the world. Despite efforts to quarantine their people, both countries are continuing to see surges in cases. Renowned vaccinologist Professor Shabir Madhi, who’s leading the trial of 2,000 volunteers in South Africa, says South Africa is even likely to still be about eight weeks away from seeing infections peak (Tech Times). Due to these factors, both South Africa and Brazil are perfect candidates for trials to test the effectiveness of ChAdOx1 nCoV-19. In addition to these trials, another larger trial is taking place in the United States. Oxford’s American pharmaceutical partner AstraZeneca plans to enroll 30,000 people in the trial this month. This trial is receiving one million dollars in funding from the United States Government and if proven effective, the goal is to manufacture three hundred million doses available to the United States by the end of the year. ~

The results of all the trials, in the United Kingdom, South Africa, Brazil, and the United States, will prove extremely important if the vaccine is effective. According to World News Network, if this outcome proves true, the team at Oxford has already coordinated with manufacturers in several countries to have about 2 billion doses available by early next year. ~

Leave a Reply